Efficacy, safety profile, and immunogenicity of alglucosidase alfa produced at the 4,000-liter scale in US children and adolescents with Pompe disease: ADVANCE, a phase IV, open-label, prospective study.

Genet Med 2018 10 22;20(10):1284-1294. Epub 2018 Mar 22.

Pediatrics, Duke University Medical Center, Durham, North Carolina, USA.

Purpose: Pompe disease results from lysosomal acid α-glucosidase (GAA) deficiency and its associated glycogen accumulation and muscle damage. Alglucosidase alfa (recombinant human GAA (rhGAA)) received approval in 2006 as a treatment for Pompe disease at the 160 L production scale. In 2010, larger-scale rhGAA was approved for patients up to 8 years old without cardiomyopathy. NCT01526785 evaluated 4,000 L rhGAA efficacy/safety in US infantile- or late-onset Pompe disease (IOPD, LOPD) patients up to 1 year old transitioned from 160 L rhGAA.

Methods: A total of 113 patients (87 with IOPD; 26 with LOPD) received 4,000 L rhGAA for 52 weeks dosed the same as previous 160 L rhGAA. Efficacy was calculated as the percentage of patients stable/improved at week 52 (without death, new requirement for invasive ventilation, left ventricular mass z-score increase >1 if baseline was >2, upright forced vital capacity decrease ≥15% predicted, or Gross Motor Function Measure-88 decrease ≥8 percentage points). Safety evaluation included an extension ≤20 months.

Results: Week 52 data was available for 104 patients, 100 of whom entered the extension. At week 52, 87/104 (83.7%) were stable/improved. Overall survival was 98.1% overall, 97.6% IOPD, 100% LOPD; 92.4% remained invasive ventilator-free (93.4% IOPD, 88.7% LOPD). Thirty-five patients had infusion-associated reactions. Eight IOPD patients died of drug-unrelated causes.

Conclusions: Most Pompe disease patients were clinically stable/improved after transitioning to 4,000 L rhGAA. Safety profiles of both rhGAA forms were consistent.

Download full-text PDF

Source
http://dx.doi.org/10.1038/gim.2018.2DOI Listing
October 2018
40 Reads

Publication Analysis

Top Keywords

pompe disease
20
4000 l rhgaa
12
iopd lopd
8
alglucosidase alfa
8
patients
8
rhgaa
7
pompe
5
disease
5
iopd
5
patients year
4
data 104
4
lopd
4
week data
4
lopd patients
4
transitioned 160 l
4
total 113
4
113 patients
4
patients iopd
4
lopd received
4
extension ≤20
4

References

(Supplied by CrossRef)

JA Lim et al.
Front Aging Neurosci 2014

PS Kishnani et al.
Am J Med Genet A 2013

YH Chien et al.
Pediatr Neonatol 2013

DH Lee et al.
JIMD Rep 2014

PS Kishnani et al.
Neurology 2007

M Nicolino et al.
Genet Med 2009

AT van der Ploeg et al.
N Engl J Med 2010

J Guo et al.
Am Health Drug Benefits 2012

DJ Russell et al.
2002

JS Gottdiener et al.
J Am Soc Echocardiogr 2004

Similar Publications